Articles by tag: dubodencel

Dubodencel Fast Track: treatment of glioblastoma and pancreatic cancer

Learn how dubodencel received its third Fast Track status from the FDA for treating glioblastoma, pancreatic cancer, and melanoma. Analysis of the dual-loading dendritic cell platform and prospects for patients.

FDA Fast Track for dendritic cell therapy dubodencel in melanoma

FDA granted Fast Track status to dubodencel (DOC1021) therapy for the treatment of unresectable melanoma. Learn how personalized dendritic cell vaccine is changing oncoimmunology.